300558 Betta Pharmaceuticals
- 40.51
- -0.29-0.71%
Betta Pharmaceuticals News
Betta Pharmaceuticals (300558.SZ): There are currently no clinical trials of PD-L1 small molecule combined with befotinib
Gelonghui, May 16 | Betta Pharmaceutical (300558.SZ) said on the investor interactive platform that the company is currently not conducting clinical trials of PD-L1 small molecules combined with befotinib.
Betta Pharmaceutical (300558.SZ): Currently, the company's Dream Factory Phase III construction plan
Gelonghui, May 10 | Betta Pharmaceutical (300558.SZ) said on the investor interactive platform that the company is currently planning to build Phase III of the company's Dream Factory. Please pay attention to the company's regular reports on the details of the company's fixed assets and projects under construction.
Betta Pharmaceuticals (300558.SZ): No drugs have been marketed or research projects for stem cell therapy or cancer vaccines
Gelonghui, May 10 | Betta Pharmaceutical (300558.SZ) said on the investor interactive platform that at present, the company has not launched drugs or established research projects related to stem cell therapy or tumor vaccines. In terms of immunotherapy, the company's R&D pipeline includes a bispecific IgG1 subtype humanized antibody BPB-101 double antibody injection project with three functions, and an oral small-molecule PD-L1 inhibitor BPI-371153 project.
Betta Pharmaceutical (300558.SZ): Currently, the BPI-16350 project second-line indicated drug registration review and approval process is in progress
Gelonghui, May 10 | Betta Pharmaceutical (300558.SZ) said on the investor interactive platform that submitting a drug registration application with second-tier indications is a routine plan for the marketing of new drugs. Currently, the BPI-16350 project second-line drug registration review and approval process is in progress. If there are plans to expand indications in the future, the company will promptly announce and disclose them.
Betta Pharmaceuticals (300558): 1Q24 performance improvement focuses on marginal positive performance trends
The 2023 and 1Q24 results are in line with our and market expectations. The company announced 2023 and 1Q24 results: revenue of 2,456 billion yuan, YoY +3.3%; net profit to mother of 348 million yuan, right
Betta Pharmaceutical (300558.SZ): Thebesilil tartrate capsules completed phase III clinical trials and obtained a summary report
Zhitong Finance App News, Betta Pharmaceutical (300558.SZ) issued an announcement. After completing the phase III clinical trial of the company's self-developed project BPI-16350 (tebesilil tartrate capsules), a clinical trial summary report has been obtained through a series of statistical data analysis work. This drug, in combination with fluvirizin, is suitable for patients with locally advanced or advanced recurrent metastatic breast cancer with positive hormone receptor (HR) and negative for human epidermal growth factor receptor 2 (HER2), which progresses after previous endocrine treatment. The study results showed that, based on the researcher's evaluation, the BPI-16350+ fluvir group was previously accepted
Express News | Betta Pharmaceuticals: BPI-16350 obtained phase III clinical trial summary report
Betta Pharmaceuticals revealed behind the layoffs: last year's profit did not increase revenue, R&D personnel fell 13%
The 2023 financial report shows that there is a phenomenon where profit increases do not increase revenue, and management expenses have dropped sharply. Some industry insiders questioned that layoffs and lower management expenses increased their current profits, but the sustainability of this method needs to be considered.
Donghai Securities released a research report on April 23 stating that it gave Betta Pharmaceuticals (300558.SZ) a purchase rating. The main reasons for the rating include: 1) the profit side is in line with expectations, and overall cost control is good;
Donghai Securities released a research report on April 23 stating that it gave Betta Pharmaceuticals (300558.SZ) a purchase rating. The main reasons for the rating include: 1) the profit side is in line with expectations, and overall cost control is good; 2) ensartinib is growing rapidly, and the volume of new drugs is expected to be marketed in 24 years; 3) the R&D pipeline continues to advance, and endogenous development and external cooperation go hand in hand. (Mainichi Keizai Shimbun)
Great Wall Guorui Securities released a research report on April 22 stating that it gave Betta Pharmaceuticals (300558.SZ) a purchase rating. The main reasons for the rating include: 1) the profit side returned to growth, and management and financial expe
Great Wall Guorui Securities released a research report on April 22 stating that it gave Betta Pharmaceuticals (300558.SZ) a purchase rating. The main reasons for the rating include: 1) the profit side returned to growth, and management and financial expenses fell sharply; 2) the rapid release of ensatinib and a solid step in internationalization; 3) the two newly launched products provided increased performance and continued progress in the research pipeline; 4) maintained the growth trend in the first quarter of this year, and EYP-1901 phase II clinical data showed treatment potential. (Mainichi Keizai Shimbun)
Southwest Securities released a research report on April 22 stating that it gave Betta Pharmaceuticals (300558.SZ) a holding rating. The main reasons for the rating include: 1) Befotinib is expected to be rapidly dosed, and the first-line NDA of enzatinib
Southwest Securities released a research report on April 22 stating that it gave Betta Pharmaceuticals (300558.SZ) a holding rating. The main reasons for the rating include: 1) Befotinib is expected to be rapidly dosed, and the first-line NDA of enzatinib has been accepted by the FDA; 2) the strategic cooperation has achieved remarkable results, and the ophthalmic indications of Heyuan Biorecombinant are worth looking forward to; 3) Early clinical progress is steady, and EGFR/C-MET dual antagonists have the potential to become a first-line treatment for EGFR-positive NSCLC. (Mainichi Keizai Shimbun)
Betta Pharmaceuticals (300558.SZ): Currently, there are no stem cell drugs on the market or research projects for diabetes treatment
Gelonghui, April 22 | Betta Pharmaceutical (300558.SZ) said on the investor interactive platform that the company currently has no stem cell drugs on the market or set up research projects to treat diabetes.
Huaan Securities released a research report on April 21 stating that it gave Beida Pharmaceuticals (300558.SZ) a purchase rating. The main reasons for the rating include: 1) high investment in R&D promotes sustainable development and rational management e
Huaan Securities released a research report on April 21 stating that it gave Beida Pharmaceuticals (300558.SZ) a purchase rating. The main reasons for the rating include: 1) high investment in R&D promotes sustainable development and rational management enhances output efficiency; 2) extending the life cycle of core products, and driving additional revenue; 3) strengthening industrial investment and licensing cooperation, and adhering to the “introduction” and “going global” strategy. (Mainichi Keizai Shimbun)
Pharmaceutical and medical stocks fluctuated and rebounded | Tonghe Pharmaceutical and Wanfu Biotech rose more than 10%, while shares such as Yahuilong, Sannuo Biotech, Xiangsheng Healthcare, Betta Pharmaceuticals, Hanyu Pharmaceutical, and Eddy Pharmaceu
Pharmaceutical and medical stocks fluctuated and rebounded | Tonghe Pharmaceutical and Wanfu Biotech rose more than 10%, while shares such as Yahuilong, Sannuo Biotech, Xiangsheng Healthcare, Betta Pharmaceuticals, Hanyu Pharmaceutical, and Eddy Pharmaceuticals rose more than 5%.
Betta Pharmaceuticals (300558): Performance is in line with expectations, the launch of new drugs and the introduction of medical insurance drive performance growth
Incident: Betta Pharmaceuticals announced its 2023 annual report and 2024 quarterly report. Achieved revenue of 2,456 million yuan in 2023 (+3.35% year over year) and realized net profit of 348 million yuan (year-on-year +139.33)
Betta Pharmaceuticals (300558): Optimistic about high growth under multi-product commercialization breakthroughs
Investment highlights Continued breakthroughs in commercialization and internationalization in 2023, and we are optimistic about high performance growth in 2024-2026. Performance: High increase in 2024Q1 revenue and continued high R&D investment. The company disclosed 2023 and 2024
Betta Pharmaceuticals (300558) 2023 Annual Report and 2024 Quarterly Report Review: Continued Product Release and Profitability Increased Significantly in the First Quarter of '24
In 2023, the company achieved revenue of 2,456 billion yuan (+3.35%), of which Q1-Q4 achieved revenue of 532/7.82/7.30/ 413 million yuan respectively; net profit to mother of 348 million yuan (+
Guolian Securities released a research report on April 21 stating that it gave Betta Pharmaceuticals (300558.SZ) an increase in holdings rating. The main reasons for the rating include: 1) the performance is in line with expectations; the launch of new dr
Guolian Securities released a research report on April 21 stating that it gave Betta Pharmaceuticals (300558.SZ) an increase in holdings rating. The main reasons for the rating include: 1) the performance is in line with expectations; the launch of new drugs and the entry into medical insurance drive performance growth; 2) there is great potential for targeted pharmacological adjuvants, dual antibodies, and ophthalmology products. (Mainichi Keizai Shimbun)
Betta Pharmaceuticals (300558) Review: Reasonable cost control and multiple varieties drive growth
incident. The company released its 2023 annual report and 2024 quarterly report. In 23, the company achieved operating income of 2,456 billion yuan (+3.35% year over year) and net profit of 348 million yuan (year-on-year +139.33)
Betta Pharmaceuticals (300558.SZ) reported first-quarter results, net profit of 98.1407 million yuan, an increase of 90.95% year-on-year
Betta Pharmaceuticals (300558.SZ) released its report for the first quarter of 2024, with revenue of 736 million yuan, compared with...
Analysis
Price Target
No Data
